Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divi...

Descripción completa

Detalles Bibliográficos
Autores principales: Oñate, Guadalupe, Pratcorona, Marta, Garrido, Ana, Artigas-Baleri, Alicia, Bataller, Alex, Tormo, Mar, Arnan, Montserrat, Vives, Susana, Coll, Rosa, Salamero, Olga, Vall-Llovera, Ferran, Sampol, Antònia, Garcia, Antoni, Cervera, Marta, Avila, Sara Garcia, Bargay, Joan, Ortín, Xavier, Nomdedéu, Josep F., Esteve, Jordi, Sierra, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162955/
https://www.ncbi.nlm.nih.gov/pubmed/37147301
http://dx.doi.org/10.1038/s41408-023-00839-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162955/
https://www.ncbi.nlm.nih.gov/pubmed/37147301
http://dx.doi.org/10.1038/s41408-023-00839-1

Ejemplares similares